Publication: L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial: Difference between revisions
Created page with "{{Publication |Title=L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial |Topic=Carnitine |Author=Cruciani, RA; Zhang, JJ; Manola, J; Cella, D; Ansari, B; Fisch, MJ |Year=2012 |Journal=Journal of clinical oncology: official journal of the American Society of Clinical Oncology |DOI=https://doi.org/10.1200/JCO.2011.40.2180 |Authors Abstract=Pur..." |
No edit summary |
||
| Line 16: | Line 16: | ||
Conclusion | Conclusion | ||
Four weeks | Four weeks of 2g of L-carnitine supplementation did not improve fatigue in patients with invasive malignancies and good performance status. | ||
}} | }} | ||
Latest revision as of 08:46, 22 July 2024
| Reference | |
|---|---|
| Title | L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial |
| Topic | Carnitine |
| Author | Cruciani, RA, Zhang, JJ, Manola, J, Cella, D, Ansari, B, Fisch, MJ |
| Year | 2012 |
| Journal | Journal of clinical oncology: official journal of the American Society of Clinical Oncology |
| DOI | https://doi.org/10.1200/JCO.2011.40.2180 |
Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.
| Purpose
L-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population. The purpose of this study was to determine the efficacy of L-carnitine supplementation as a treatment for fatigue in patients with cancer. Patients and Methods In this double-blind, placebo-controlled trial, patients with invasive malignancies and fatigue were randomly assigned to either 2 g/d of L-carnitine oral supplementation or matching placebo. The primary end point was the change in average daily fatigue from baseline to week 4 using the Brief Fatigue Inventory (BFI). Results Three hundred seventy-six patients were randomly assigned to treatment with L-carnitine supplementation or placebo. L-carnitine supplementation resulted in significant carnitine plasma level increase by week 4. The primary outcome, fatigue, measured using the BFI, improved in both arms compared with baseline (L-carnitine: 0.96, 95% CI, 1.32 to 0.60; placebo: 1.11, 95% CI 1.44 to 0.78). There were no statistically significant differences between arms (P .57). Secondary outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy–Fatigue instrument, depression, and pain, did not show significant difference between arms. A separate analysis of patients who were carnitine-deficient at baseline did not show statistically significant improvement in fatigue or other outcomes after L-carnitine supplementation. Conclusion Four weeks of 2g of L-carnitine supplementation did not improve fatigue in patients with invasive malignancies and good performance status. |
This publication is referenced in the following studies: